Non-Hodgkin Lymphoma | Specialty

The non-hodgkin lymphoma condition center is a comprehensive resource for clinical news and expert insights on non-hodgkin lymphoma. Read more at OncLive.

The OncFive: Top Oncology Articles for the Week of 7/13

July 19th 2025

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL

July 18th 2025

The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

When to Consider Allogeneic Transplant in CTCL & Clinical Pearls for Community Providers

July 18th 2025

Panelists discuss how stem cell transplantation is considered primarily for younger patients or aggressive CTCL variants, balancing timing, remission status, and potential risks, while also emphasizing the value of early referral and specialized guidance for advanced disease.

Clinical Perspectives: When to Revisit a Prior Therapies in Mycosis Fungoides and Sézary Syndrome

July 18th 2025

Panelists discuss how decisions about reintroducing previous therapies for CTCL are based on prior tolerance, current disease state, and the reason for stopping treatment, with flexibility to recycle effective agents when appropriate.

ELM-2 Data Display Long-Term Efficacy and Safety of Odronextamab in R/R Follicular Lymphoma

July 15th 2025

Stefano Luminari, MD, discusses unmet needs for patients with follicular lymphoma, updated data from the ELM-2 trial, and infection risk management advice.

Monitoring Mogamulizuma: Managing and Differentiating Drug vs. Disease-Related Rash

July 11th 2025

Panelists discuss how to differentiate Mogamulizumab-associated rash from cutaneous T-cell lymphoma (CTCL) using clinical clues, biopsy findings, and molecular studies, and how treatment may be modified based on rash severity and characteristics.

Personalizing Care: Treatment Decisions in Sézary Syndrome

July 11th 2025

Panelists discuss how to sequence and personalize therapy for Sézary syndrome, with Mogamulizumab often used as first-line treatment due to potential for durable remission, followed by HDAC inhibitors, photopheresis, or Alemtuzumab depending on disease progression and transplant planning.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

Expert Perspectives: Combination Therapies in Advanced-Stage MF

July 2nd 2025

Panelists discuss how to integrate skin-directed therapies with systemic treatments for CTCL, emphasizing individualized strategies based on disease compartment, cautious layering of treatments, management of bacterial colonization (especially Staph aureus), and use of adjunctive measures like bleach baths for optimizing skin health.

Treatment Challenges in Advanced Mycosis Fungoides: High Blood Burden or Nodal Disease

July 2nd 2025

Panelists discuss how to manage advanced-stage mycosis fungoides with nodal or visceral involvement by adapting treatments typically used for peripheral T-cell lymphoma, including single-agent chemotherapy and HDAC inhibitors, while accounting for long-term toxicities and unique dose considerations due to patient fragility and tumor biology.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025

July 1st 2025

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

FDA Removes REMS Programs for All Currently Approved CD19- and BCMA-Directed CAR T-Cell Therapies in Hematologic Malignancies

June 30th 2025

The FDA has eliminated REMS programs for BCMA- and CD19-directed autologous CAR T-cell therapies approved for multiple myeloma and select types of lymphoma/leukemia.

FDA Approves Changes to Monitoring Requirements, Removal of REMS Programs for Liso-Cel and Ide-Cel in B-Cell Malignancies

June 27th 2025

The FDA updated the labels for liso-cel and ide-cel to reduce monitoring select requirements and remove REMS programs for the CAR T-cell therapies.

Future of DLBCL Therapy Hinges on Optimal Use of CAR T-Cell Therapy, Bispecifics, and Other Novel Strategies

June 26th 2025

Alexey Danilov, MD, PhD, highlights the importance of re-evaluating sequencing strategies amid a growing arsenal of targeted therapies in DLBCL.

Strategic Sequencing in Advanced Mycosis Fungoides: Choosing Between Immunomodulatory, HDAC, and Targeted Therapies

June 25th 2025

Panelists discuss how individualized treatment plans must consider disease location, drug access, comorbidities, and newer therapies like HDAC inhibitors and immune checkpoint inhibitors, while emphasizing the importance of managing expectations and monitoring side effects.

Advanced-Stage Mycosis Fungoides: Navigating Treatment Decisions Amid a Complex Therapeutic Landscape

June 25th 2025

Panelists discuss how treatment goals and selection for advanced-stage cutaneous T-cell lymphoma depend on disease compartmentalization, with therapies like brentuximab vedotin and mogamulizumab being used based on specific disease characteristics and toxicity profiles.

Dr Vose on the Durability of Response to Epcoritamab Monotherapy in DLBCL

June 24th 2025

Julie M. Vose, MD, MBA, discusses the durability of response to epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

Five Under 5: Top Oncology Videos for the Week of 6/15

June 22nd 2025

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

The OncFive: Top Oncology Articles for the Week of 6/15

June 21st 2025

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

Dr Abramson on Findings with Glofitamab, Gemcitabine and Oxaliplatin in R/R DLBCL

June 20th 2025

Jeremy Abramson, MD, discusses the use of glofitamab with gemcitabine and oxaliplatin in patients with relapsed/refractory DLBCL.